DV
Dividend Vision

SMMT — Summit Therapeutics Inc.

Summit Therapeutics Inc. (SMMT)

Total return is 34.8% over the past 11.4 years, 312.3 points behind SPY at 347.1%. Its deepest 1-year drawdown was 53.5%.

SMMT is an equity stock that focuses on the biotech and pharmaceutical sector. The fund does not currently distribute dividends to shareholders, making it unsuitable for income-focused investors seeking regular dividend payments. This holding appeals primarily to growth-oriented investors seeking exposure to therapeutic development companies rather than those pursuing dividend income strategies.

SMMT key facts

Asset type
Stock
Asset class
Equity
Inception date
03/04/2015
Distribution frequency
None
Last close
$13.35
Market cap
$10,649,958,400
Average volume
9748872.0
Beta
-1.24
Payout ratio
0.0
Forward P/E
3.7216
EPS
$-1.06